Advertisement

Comparison of the Impact of Short (<1 Year) and Long-Term (≥1 Year) Clopidogrel Use Following Percutaneous Coronary Intervention on Mortality

Published:September 15, 2008DOI:https://doi.org/10.1016/j.amjcard.2008.06.058
      The optimal duration of clopidogrel administration after percutaneous coronary intervention (PCI) remains unknown. Clopidogrel is currently recommended for minimums of 1 and 12 months after bare-metal stent and drug-eluting stent implantation, respectively. To determine the impact of clopidogrel discontinuation 1 year after PCI, the outcomes of 530 consecutive patients who underwent PCI from January 2004 to July 2006, were free of cardiovascular events for 6 months after PCI, and had follow-up available for >12 months were examined. The outcomes of patients who received clopidogrel for ≥1 year were compared with those of patients who received it for <1 year. The mean age was 65 ± 9 years. Patients often presented with acute coronary syndromes (57%), and 85% received drug-eluting stents. Clopidogrel was used for ≥1 year and for <1 year in 341 and 189 patients, respectively. During a mean follow-up period of 2.4 ± 0.8 years, 40 patients (8%) died, 21 (4%) had acute myocardial infarctions, and 89 (17%) underwent repeat coronary revascularization. Compared with patients with clopidogrel administration for <1 year after PCI, those who received clopidogrel for ≥1 year had lower mortality (14.8% vs 3.5%, p <0.001). On multivariate analysis, clopidogrel use for ≥1 year was associated with lower mortality (hazard ratio 0.28, 95% confidence interval 0.14 to 0.59), independent of traditional cardiovascular risk factors, clinical presentation, and the use of drug-eluting stents. In conclusion, the use of clopidogrel for ≥1 year after PCI was associated with lower mortality.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • King III, S.B.
        • Smith Jr, S.C.
        • Hirshfeld Jr, J.W.
        • Jacobs A.K.
        • Morrison D.A.
        • Williams D.O.
        • Feldman T.E.
        • Kern M.J.
        • O'Neill W.W.
        • Schaff H.V.
        • et al.
        2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention.
        J Am Coll Cardiol. 2008; 51: 172-209
        • Blomkalns A.L.
        • Roe M.T.
        • Peterson E.D.
        • Ohman E.M.
        • Fraulo E.S.
        • Gibler W.B.
        Guideline implementation research: exploring the gap between evidence and practice in the CRUSADE quality improvement initiative.
        Acad Emerg Med. 2007; 14: 949-954
        • Bottorff M.B.
        • Nutescu E.A.
        • Spinler S.
        Antiplatelet therapy in patients with unstable angina and non-ST-segment-elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative.
        Pharmacotherapy. 2007; 27: 1145-1162
        • Mehta S.R.
        • Yusuf S.
        • Peters R.J.
        • Bertrand M.E.
        • Lewis B.S.
        • Natarajan M.K.
        • Malmberg K.
        • Rupprecht H.
        • Zhao F.
        • Chrolavicius S.
        • et al.
        • Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
        Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.
        Lancet. 2001; 358: 527-533
        • Steinhubl S.R.
        • Berger P.B.
        • Mann III, J.T.
        • Fry E.T.
        • DeLago A.
        • Wilmer C.
        • Topol E.J.
        • CREDO Investigators
        Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial.
        JAMA. 2002; 288: 2411-2420
        • Sabatine M.S.
        • Cannon C.P.
        • Gibson C.M.
        • López-Sendón J.L.
        • Montalescot G.
        • Theroux P.
        • Lewis B.S.
        • Murphy S.A.
        • McCabe C.H.
        • Braunwald E.
        • Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)–Thrombolysis In Myocardial Infarction (TIMI) 28 Investigators
        Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study.
        JAMA. 2005; 294: 1224-1232
        • Yusuf S.
        • Zhao F.
        • Mehta S.R.
        • Chrolavicius S.
        • Tognoni G.
        • Fox K.K.
        Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
        N Engl J Med. 2001; 16 (494–502): 345
        • CAPRIE Steering Committee
        A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Iakovou I.
        • Schmidt T.
        • Bonizzoni E.
        • Ge L.
        • Sangiorgi G.M.
        • Stankovic G.
        • Airoldi F.
        • Chieffo A.
        • Montorfano M.
        • Carlino M.
        • et al.
        Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.
        JAMA. 2005; 293: 2126-2130
        • McFadden E.P.
        • Stabile E.
        • Regar E.
        • Cheneau E.
        • Ong A.T.
        • Kinnaird T.
        • Suddath W.O.
        • Weissman N.J.
        • Torguson R.
        • Kent K.M.
        • et al.
        Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy.
        Lancet. 2004; 364: 1519-1521
        • Pfisterer M.
        • Brunner-La Rocca H.P.
        • Buser P.T.
        • Rickenbacher P.
        • Hunziker P.
        • Mueller C.
        • Jeger R.
        • Bader F.
        • Osswald S.
        • Kaiser C.
        • BASKET-LATE Investigators
        Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents.
        J Am Coll Cardiol. 2006; 48: 2584-2591
        • Ho P.M.
        • Fihn S.D.
        • Wang L.
        • Bryson C.L.
        • Lowy E.
        • Maynard C.
        • Magid D.J.
        • Peterson E.D.
        • Jesse R.L.
        • Rumsfeld J.S.
        Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome.
        Am Heart J. 2007; 154: 846-851
        • Ho P.M.
        • Peterson E.D.
        • Wang L.
        • Magid D.J.
        • Fihn S.D.
        • Larsen G.C.
        • Jesse R.A.
        • Rumsfeld J.S.
        Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome.
        JAMA. 2008; 299: 532-539
        • Steiner J.F.
        • Koepsell T.D.
        • Fihn S.D.
        • Inui T.S.
        A general method of compliance assessment using centralized pharmacy records.
        Med Care. 1988; 26: 814-823
        • Eisenstein E.L.
        • Anstrom K.J.
        • Kong D.F.
        • Shaw L.K.
        • Tuttle R.H.
        • Mark D.B.
        • Kramer J.M.
        • Harrington R.A.
        • Matchar D.B.
        • Kandzari D.E.
        • et al.
        Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.
        JAMA. 2007; 297: 159-168
        • Angiolillo D.J.
        • Fernandez-Ortiz A.
        • Bernardo E.
        • Ramírez C.
        • Sabaté M.
        • Jimenez-Quevedo P.
        • Hernández R.
        • Moreno R.
        • Escaned J.
        • Alfonso F.
        • et al.
        Clopidogrel withdrawal is associated with proinflammatory and prothrombotic effects in patients with diabetes and coronary artery disease.
        Diabetes. 2006; 55: 780-784
        • Geisler T.
        • Anders N.
        • Paterok M.
        • Langer H.
        • Stellos K.
        • Lindemann S.
        • Herdeg C.
        • May A.E.
        • Gawaz M.
        Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation.
        Diabetes Care. 2007; 30: 372-374
        • Joner M.
        • Finn A.V.
        • Farb A.
        • Mont E.K.
        • Kolodgie F.D.
        • Ladich E.
        • Kutys R.
        • Skorija K.
        • Gold H.K.
        • Virmani R.
        Pathology of drug-eluting stents in man: delayed healing and late thrombotic risk.
        J Am Coll Cardiol. 2006; 48: 193-202
        • Cutlip D.E.
        • Baim D.S.
        • Ho K.K.
        • Popma J.J.
        Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
        Circulation. 2001; 103: 1967-1971
        • Bhatt D.L.
        • Fox K.A.
        • Hacke W.
        • Berger P.B.
        • Black H.R.
        • Boden W.E.
        • Cacoub P.
        • Cohen E.A.
        • Creager M.A.
        • Easton J.D.
        • et al.
        • CHARISMA Investigators
        Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
        N Engl J Med. 2006; 354: 1706-1717